Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision health and longevity care, today announced a strategic collaboration with Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, to launch novel proteomic testing services designed to advance the science of human longevity.

Human Longevity will incorporate two of Alamar's NULISAseq™ multiplexed panels that profile human inflammation and neurological health into its service offering.  

1. NULISAseq Inflammation Panel 250 – provides precise detection and monitoring of chronic inflammation, a central driver of aging and multiple age-related diseases.
2. NULISAseq CNS Disease Panel 120 – enables early detection and monitoring of key biomarkers involved in neurodegenerative and neurological disorders, aiming to provide unprecedented insights into brain health and resilience.

By leveraging Alamar's ultra-high sensitivity proteomics platform, NULISA™, and HLI's decade of experience in integrating genomics, imaging, and multi-omics data from over 10,000 clients, clinicians and researchers will gain access to powerful new tools to measure biological processes that directly impact healthspan and lifespan.

"Proteomics is the next frontier in longevity medicine. By adding high-resolution protein measurements to our existing genomics and imaging platform, we are moving closer to truly predictive and preventive healthcare," said Wei-Wu He, Ph.D., Executive Chairman of Human Longevity, Inc. "Our collaboration with Alamar allows us to bring cutting-edge science directly into clinical practice for the benefit of our clients."

"We're proud to collaborate with Human Longevity to help advance the science of healthy aging," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "It's incredibly meaningful that a trailblazer in longevity research has chosen our precision proteomics platform to drive real-world applications that support longer, healthier lives."

The panels will be integrated into HLI's Executive Health and 100+ Longevity precision health programs later this year, with initial availability to HLI members. This initiative underscores the commitment of both companies to advance longevity science through AI, multi-omics, and next-generation diagnostics.

About Human Longevity, Inc.

Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations aimed at identifying and preventing disease long before symptoms arise. To learn more or how to enroll, visit www.humanlongevity.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com

Media Contact:
[email protected] 
www.humanlongevity.com

SOURCE Human Longevity, Inc.